Modification  ||| S:0 E:13 ||| NNP
and  ||| S:13 E:17 ||| CC
implementation  ||| S:17 E:32 ||| NN
of  ||| S:32 E:35 ||| IN
NCCN  ||| S:35 E:40 ||| NNP
guidelines  ||| S:40 E:51 ||| NNS
on  ||| S:51 E:54 ||| IN
hepatobiliary  ||| S:54 E:68 ||| JJ
cancers  ||| S:68 E:76 ||| NNS
in  ||| S:76 E:79 ||| IN
the  ||| S:79 E:83 ||| DT
Middle  ||| S:83 E:90 ||| NNP
East  ||| S:90 E:95 ||| NNP
and  ||| S:95 E:99 ||| CC
North  ||| S:99 E:105 ||| NNP
Africa  ||| S:105 E:112 ||| NNP
region  ||| S:112 E:119 ||| NN
The  ||| S:119 E:123 ||| DT
NCCN  ||| S:123 E:128 ||| NNP
Clinical  ||| S:128 E:137 ||| NNP
Practice  ||| S:137 E:146 ||| NNP
Guidelines  ||| S:146 E:157 ||| NNP
in  ||| S:157 E:160 ||| IN
Oncology  ||| S:160 E:169 ||| NNP
( ||| S:169 E:170 ||| -LRB-
NCCN  ||| S:170 E:175 ||| NNP
Guidelines ||| S:175 E:185 ||| NNP
)  ||| S:185 E:187 ||| -RRB-
on  ||| S:187 E:190 ||| IN
Hepatobiliary  ||| S:190 E:204 ||| NNP
Cancers  ||| S:204 E:212 ||| NNP
address  ||| S:212 E:220 ||| NN
hepatocellular  ||| S:220 E:235 ||| NN
cancer ||| S:235 E:241 ||| NN
,  ||| S:241 E:243 ||| ,
cancer  ||| S:243 E:250 ||| NN
of  ||| S:250 E:253 ||| IN
the  ||| S:253 E:257 ||| DT
gallbladder ||| S:257 E:268 ||| NN
,  ||| S:268 E:270 ||| ,
extrahepatic  ||| S:270 E:283 ||| JJ
cholangiocarcinoma ||| S:283 E:301 ||| NN
,  ||| S:301 E:303 ||| ,
and  ||| S:303 E:307 ||| CC
intrahepatic  ||| S:307 E:320 ||| JJ
cholangiocarcinoma ||| S:320 E:338 ||| NN
.  ||| S:338 E:340 ||| .
Hepatocellular  ||| S:340 E:355 ||| JJ
cancer  ||| S:355 E:362 ||| NN
incidence  ||| S:362 E:372 ||| NN
is  ||| S:372 E:375 ||| VBZ
higher  ||| S:375 E:382 ||| JJR
in  ||| S:382 E:385 ||| IN
the  ||| S:385 E:389 ||| DT
Middle  ||| S:389 E:396 ||| NNP
East  ||| S:396 E:401 ||| NNP
and  ||| S:401 E:405 ||| CC
North  ||| S:405 E:411 ||| NNP
Africa  ||| S:411 E:418 ||| NNP
( ||| S:418 E:419 ||| -LRB-
MENA ||| S:419 E:423 ||| NNP
)  ||| S:423 E:425 ||| -RRB-
region  ||| S:425 E:432 ||| NN
than  ||| S:432 E:437 ||| IN
in  ||| S:437 E:440 ||| IN
the  ||| S:440 E:444 ||| DT
West ||| S:444 E:448 ||| NNP
,  ||| S:448 E:450 ||| ,
and  ||| S:450 E:454 ||| CC
hepatitis  ||| S:454 E:464 ||| NNP
B  ||| S:464 E:466 ||| NNP
and  ||| S:466 E:470 ||| CC
C  ||| S:470 E:472 ||| NNP
infections  ||| S:472 E:483 ||| NNS
are  ||| S:483 E:487 ||| VBP
particularly  ||| S:487 E:500 ||| RB
important ||| S:500 E:509 ||| JJ
;  ||| S:509 E:511 ||| :
the  ||| S:511 E:515 ||| DT
incidence  ||| S:515 E:525 ||| NN
of  ||| S:525 E:528 ||| IN
gallbladder  ||| S:528 E:540 ||| JJ
cancer  ||| S:540 E:547 ||| NN
is  ||| S:547 E:550 ||| VBZ
among  ||| S:550 E:556 ||| IN
the  ||| S:556 E:560 ||| DT
highest  ||| S:560 E:568 ||| JJS
in  ||| S:568 E:571 ||| IN
the  ||| S:571 E:575 ||| DT
world ||| S:575 E:580 ||| NN
.  ||| S:580 E:582 ||| .
Regional  ||| S:582 E:591 ||| JJ
problems  ||| S:591 E:600 ||| NNS
include  ||| S:600 E:608 ||| VBP
delay  ||| S:608 E:614 ||| NN
in  ||| S:614 E:617 ||| IN
diagnosis ||| S:617 E:626 ||| NN
,  ||| S:626 E:628 ||| ,
shortage  ||| S:628 E:637 ||| NN
of  ||| S:637 E:640 ||| IN
trained  ||| S:640 E:648 ||| JJ
staff ||| S:648 E:653 ||| NN
,  ||| S:653 E:655 ||| ,
and  ||| S:655 E:659 ||| CC
insufficient  ||| S:659 E:672 ||| JJ
liver  ||| S:672 E:678 ||| NN
transplant  ||| S:678 E:689 ||| NN
facilities ||| S:689 E:699 ||| NNS
.  ||| S:699 E:701 ||| .
Furthermore ||| S:701 E:712 ||| RB
,  ||| S:712 E:714 ||| ,
costs  ||| S:714 E:720 ||| VBZ
associated  ||| S:720 E:731 ||| VBN
with  ||| S:731 E:736 ||| IN
molecular  ||| S:736 E:746 ||| JJ
and  ||| S:746 E:750 ||| CC
targeted  ||| S:750 E:759 ||| JJ
therapies  ||| S:759 E:769 ||| NNS
are  ||| S:769 E:773 ||| VBP
an  ||| S:773 E:776 ||| DT
increasing  ||| S:776 E:787 ||| JJ
concern ||| S:787 E:794 ||| NN
.  ||| S:794 E:796 ||| .
A  ||| S:796 E:798 ||| DT
committee  ||| S:798 E:808 ||| NN
was  ||| S:808 E:812 ||| VBD
formed ||| S:812 E:818 ||| VBN
,  ||| S:818 E:820 ||| ,
consisting  ||| S:820 E:831 ||| VBG
of  ||| S:831 E:834 ||| IN
leading  ||| S:834 E:842 ||| VBG
specialists  ||| S:842 E:854 ||| NNS
and  ||| S:854 E:858 ||| CC
decision-makers  ||| S:858 E:874 ||| NNS
from  ||| S:874 E:879 ||| IN
the  ||| S:879 E:883 ||| DT
region ||| S:883 E:889 ||| NN
,  ||| S:889 E:891 ||| ,
with  ||| S:891 E:896 ||| IN
each  ||| S:896 E:901 ||| DT
member  ||| S:901 E:908 ||| NN
being  ||| S:908 E:914 ||| VBG
tasked  ||| S:914 E:921 ||| NN
to  ||| S:921 E:924 ||| TO
suggest  ||| S:924 E:932 ||| VB
modifications  ||| S:932 E:946 ||| NNS
to  ||| S:946 E:949 ||| TO
the  ||| S:949 E:953 ||| DT
existing  ||| S:953 E:962 ||| JJ
guidelines  ||| S:962 E:973 ||| NNS
based  ||| S:973 E:979 ||| VBN
on  ||| S:979 E:982 ||| IN
review  ||| S:982 E:989 ||| NN
of  ||| S:989 E:992 ||| IN
the  ||| S:992 E:996 ||| DT
literature  ||| S:996 E:1007 ||| NN
and  ||| S:1007 E:1011 ||| CC
consultations  ||| S:1011 E:1025 ||| NN
with  ||| S:1025 E:1030 ||| IN
local  ||| S:1030 E:1036 ||| JJ
colleagues ||| S:1036 E:1046 ||| NNS
.  ||| S:1046 E:1048 ||| .
This  ||| S:1048 E:1053 ||| DT
committee  ||| S:1053 E:1063 ||| NN
met  ||| S:1063 E:1067 ||| VBD
as  ||| S:1067 E:1070 ||| IN
a  ||| S:1070 E:1072 ||| DT
group ||| S:1072 E:1077 ||| NN
,  ||| S:1077 E:1079 ||| ,
and  ||| S:1079 E:1083 ||| CC
then  ||| S:1083 E:1088 ||| RB
continued  ||| S:1088 E:1098 ||| VBN
to  ||| S:1098 E:1101 ||| TO
discuss  ||| S:1101 E:1109 ||| VB
and  ||| S:1109 E:1113 ||| CC
debate  ||| S:1113 E:1120 ||| VB
the  ||| S:1120 E:1124 ||| DT
suggested  ||| S:1124 E:1134 ||| JJ
modifications  ||| S:1134 E:1148 ||| NNS
electronically ||| S:1148 E:1162 ||| RB
.  ||| S:1162 E:1164 ||| .
Several  ||| S:1164 E:1172 ||| JJ
recommendations  ||| S:1172 E:1188 ||| NNS
were  ||| S:1188 E:1193 ||| VBD
finalized  ||| S:1193 E:1203 ||| VBN
after  ||| S:1203 E:1209 ||| IN
vigorous  ||| S:1209 E:1218 ||| JJ
debate ||| S:1218 E:1224 ||| NN
.  ||| S:1224 E:1226 ||| .
The  ||| S:1226 E:1230 ||| DT
final  ||| S:1230 E:1236 ||| JJ
approved  ||| S:1236 E:1245 ||| JJ
recommendations  ||| S:1245 E:1261 ||| NNS
were  ||| S:1261 E:1266 ||| VBD
then  ||| S:1266 E:1271 ||| RB
presented  ||| S:1271 E:1281 ||| VBN
in  ||| S:1281 E:1284 ||| IN
April  ||| S:1284 E:1290 ||| NNP
2009  ||| S:1290 E:1295 ||| CD
to  ||| S:1295 E:1298 ||| TO
the  ||| S:1298 E:1302 ||| DT
chair  ||| S:1302 E:1308 ||| NN
of  ||| S:1308 E:1311 ||| IN
the  ||| S:1311 E:1315 ||| DT
NCCN  ||| S:1315 E:1320 ||| NNP
Hepatobiliary  ||| S:1320 E:1334 ||| NNP
Cancers  ||| S:1334 E:1342 ||| NNP
Panel  ||| S:1342 E:1348 ||| NNP
for  ||| S:1348 E:1352 ||| IN
onward  ||| S:1352 E:1359 ||| JJ
transmission  ||| S:1359 E:1372 ||| NN
and  ||| S:1372 E:1376 ||| CC
approval ||| S:1376 E:1384 ||| NN
.  ||| S:1384 E:1386 ||| .
This  ||| S:1386 E:1391 ||| DT
project  ||| S:1391 E:1399 ||| NN
represents  ||| S:1399 E:1410 ||| VBZ
an  ||| S:1410 E:1413 ||| DT
effort  ||| S:1413 E:1420 ||| NN
to  ||| S:1420 E:1423 ||| TO
modify  ||| S:1423 E:1430 ||| VB
and  ||| S:1430 E:1434 ||| CC
implement  ||| S:1434 E:1444 ||| VB
the  ||| S:1444 E:1448 ||| DT
NCCN  ||| S:1448 E:1453 ||| NNP
Guidelines  ||| S:1453 E:1464 ||| NNP
on  ||| S:1464 E:1467 ||| IN
Hepatobiliary  ||| S:1467 E:1481 ||| NNP
Cancers  ||| S:1481 E:1489 ||| NNP
in  ||| S:1489 E:1492 ||| IN
the  ||| S:1492 E:1496 ||| DT
MENA  ||| S:1496 E:1501 ||| NNP
region ||| S:1501 E:1507 ||| NN
,  ||| S:1507 E:1509 ||| ,
while  ||| S:1509 E:1515 ||| IN
taking  ||| S:1515 E:1522 ||| VBG
into  ||| S:1522 E:1527 ||| IN
consideration  ||| S:1527 E:1541 ||| NN
local  ||| S:1541 E:1547 ||| JJ
differences  ||| S:1547 E:1559 ||| NNS
in  ||| S:1559 E:1562 ||| IN
patient  ||| S:1562 E:1570 ||| NN
and  ||| S:1570 E:1574 ||| CC
disease  ||| S:1574 E:1582 ||| NN
characteristics ||| S:1582 E:1597 ||| NNS
.  ||| S:1597 E:1599 ||| .
The  ||| S:1599 E:1603 ||| DT
hope  ||| S:1603 E:1608 ||| NN
is  ||| S:1608 E:1611 ||| VBZ
that  ||| S:1611 E:1616 ||| IN
this  ||| S:1616 E:1621 ||| DT
will  ||| S:1621 E:1626 ||| MD
form  ||| S:1626 E:1631 ||| VB
the  ||| S:1631 E:1635 ||| DT
basis  ||| S:1635 E:1641 ||| NN
of  ||| S:1641 E:1644 ||| IN
future  ||| S:1644 E:1651 ||| JJ
local ||| S:1651 E:1656 ||| JJ
,  ||| S:1656 E:1658 ||| ,
regional ||| S:1658 E:1666 ||| JJ
,  ||| S:1666 E:1668 ||| ,
and  ||| S:1668 E:1672 ||| CC
international  ||| S:1672 E:1686 ||| JJ
cooperation  ||| S:1686 E:1698 ||| NN
in  ||| S:1698 E:1701 ||| IN
guideline  ||| S:1701 E:1711 ||| NN
development  ||| S:1711 E:1723 ||| NN
and  ||| S:1723 E:1727 ||| CC
research ||| S:1727 E:1735 ||| NN
.  ||| S:1735 E:1737 ||| .
